论文部分内容阅读
慢性肾衰 (ＣＲＦ)患者的贫血 ,直接影响了患者的预后。尽管透析技术发展普及 ,明显延长ＣＲＦ患者的生命。但是 ,由于长期严重的肾性贫血仍然是影响患者的生存质量及长期存活的重要因素。 1986年以来利用遗传基因重组技术制备的人红细胞生成素 (γＨｕＥＰＯ)被广泛用于临床 ,
Anemia in patients with chronic renal failure (CRF) directly affects the patient’s prognosis. Although the popularity of dialysis technology, CRF patients significantly prolong the life. However, due to long-term severe renal anemia is still an important factor affecting the quality of life and long-term survival of patients. Since 1986, human erythropoietin (γHuEPO) prepared by genetic recombination technology has been widely used in clinic,